Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer
AUTHORS
Rodilla
AM ,
Valanparambil
RM ,
Mack
PC ,
Hsu
CY ,
Cagan
J ,
Tavolacci
SC ,
Carreño
JM ,
Brody
R ,
Moore
A ,
King
JC ,
Gomez
JE ,
Rohs
N ,
Rolfo
C ,
Bunn
PA ,
Gerber
DE ,
Minna
JD ,
Krammer
F ,
Ramalingam
SS ,
García-Sastre
A ,
Shyr
Y ,
Ahmed
R ,
Hirsch
FR ,
. Cancer cell. 2023 10 13; ().
- PMID: 37863065 [PubMed].
ABSTRACT
Patients diagnosed with lung cancer (LC) exhibit increased susceptibility to SARS-CoV-2 infection. Rodilla et al. monitor the levels of plasma anti-nucleocapsid antibodies within a cohort of fully vaccinated LC patients and reveal that the actual infection rate is nearly twice the documented rate, indicating a significant prevalence of unreported cases.
Tags: 2023 faculty publications